Kornimate/medical-research-clean huggingface dataset:
metabolic and psychological changes associated with menopause among women with hiv

Conditions: HIV Infections; Menopause

Summary: this study will investigate the prevalence and extent of both metabolic and psychosocial changes associated with the menopause transition over 1 year among women with hiv compared to women without hiv of similar age, weight, menstrual status, and ethnic background. it is hypothesized that hiv positive women will demonstrate increased abdominal fat, abnormal cholesterol and blood sugar levels, reduced bone density, and greater psychosocial challenges than hiv negative women during the menopause transition.

treatment with combination antiretroviral therapy (art) has resulted in substantial improvement in survival among women living with hiv in the united states, many of whom have entered or will soon enter the menopause transition. significant changes are seen across the menopause transition among women without hiv including increased abdominal fat and waist circumference, reduced muscle mass, and changes in lipids, glucose metabolism and bone density. hiv and potentially art use have been associated with similar manifestations such as reduced bone density, changes in lipid and glucose metabolism, and body composition, though little is known regarding how the virus may influence or exacerbate such changes across the menopause transition. in addition to metabolic factors, menopause has been associated with changes in mood state, decreased quality of life, and presence of vasomotor symptoms among women without hiv. psychosocial indices, such as depression and decreased quality of life are common among women with hiv, and may manifest or worsen during the menopause transition. however, research investigating the presence and acuity of these symptoms among women with hiv during menopause is limited.

Eligibility criteria:
inclusion criteria: 1. females age 45 -52. 2. females in the perimenopausal transition characterized by the presence of abnormal menstrual function, defined as less than 3 periods in the past 3 months, 1 cycle \>60 days in length in the prior 6 months, or irregular menses in 2 or more cycles within the past 6 months. women who have been amenorrheic for \>12 months will not be eligible. 3. women with hiv must have previously documented hiv and be receiving a stable treatment regimen for \> 3 months. exclusion criteria: 1. use of estrogen, combination hormone replacement therapy, oral contraceptive pills/patches, depo provera, glucocorticoids, testosterone, growth hormone or other anabolic steroids within the past 6 months. 2. diabetes and current use of insulin, or medications known to affect glucose or insulin levels. 3. positive pregnancy test or recently pregnant within the past year or lactating. 4. presence of active cancers. 5. current use of bisphosphonates, or a diagnosis of paget's disease or other illnesses known to affect bone (use of calcium and vitamin d will be permitted). 6. opportunistic infection within 3 months of study participation (hiv positive subjects). -

Keywords: hiv women menopause dyslipidemia bone mineral density
childhood obesity prevention

Conditions: Childhood Obesity; Diabetes

Summary: to develop and evaluate a culturally appropriate childhood obesity prevention program targeting primary care-givers of third grade students. the cognitive-behavioral lifestyle intervention consisted of eight, 90-minute sessions at the elementary schools. primary outcome: body mass index of third graders and their primary care-givers primary objective: to engage primary care-givers of third grand children in identifying and creating health promoting culturally appropriate environments for young children.

the sessions include information about energy balance, portion control, appropriate amounts and types of physical activity, physical inactivity, nutrition and self-esteem. the influence of the primary care-giver on the children's physical activity and nutritional behaviors may lead to greater or lesser rates of obesity in childhood and eventually lead to adult obesity. therefore, the intention of this intervention is to educate primary care-givers so as to effect change (in a positive way) in the children they care for. assessment on steps taken, bmi, percent body fat, diet, self reported physical activity and diet will be used to evaluate the impact of the sessions.

Eligibility criteria:
inclusion criteria: * currently having a third grader attending public school exclusion criteria: * none

Keywords: obesity prevention childhood children primary care-giver
study of efficacy and safety of investigational treatment in patients with hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: this is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate at193 in approximately 44 participants with hs. the treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. the primary objective of this study is to evaluate the safety and tolerability of at193. the secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of hs.


Eligibility criteria:
inclusion criteria: * diagnosis of hs or signs and symptoms consistent with hs for at least 3 months before screening in the judgment of the investigator. * stable disease for at least 2 months before screening in the judgment of the investigator. * a woman of childbearing potential must use appropriate contraceptive measures during the study period. * a woman of childbearing potential must have a negative urine pregnancy test result at screening. * written informed consent must be obtained before any study procedure is performed. exclusion criteria: * pregnant or breastfeeding. * any active skin disease that may interfere with evaluation of study drug or outcome assessment. * history or evidence of a clinically significant disorder, condition, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion in the judgment of the investigator. * change in smoking or marijuana history within 3 months before day 1 or planned during study period.
synchronous and asynchronous telerehabilitation methods in patients with shoulder tendinopathy

Conditions: Tendinopathy; Shoulder Pain

Summary: this study is a randomized controlled trial conducted to compare the effects of synchronous and asynchronous telerehabilitation programs on pain, disability, and quality of life parameters in patients with shoulder tendinopathy in the marmara university physiotherapy and rehabilitation department.


Eligibility criteria:
inclusion criteria: * participants between the ages of 18-65, * who had access to the internet and smartphone, * had the ability to conduct video calls included in the study. exclusion criteria: * participants were excluded if they had covid-19, * had surgery in the last 6 months, * had neurological and psychological disorders, * received physiotherapy treatment. * had surgery in the last 6 months, * had a condition that prevented them from exercising.
diagnostic value of hyperbilirubinaemia as a predictive factor for appendiceal perforation in acute appendicitis

Conditions: Perforated Appendicitis

Summary: the values of laboratory examinations which are useful for the diagnoses of appendicitis are white blood cell count (wbc), c-reactive protein (crp) and erythrocyte blood sedimentation rate (esr). however up to date there is no laboratory marker for the pre-operative diagnosis of appendiceal perforation in acute appendicitis. recently hyperbilirubinaemia has been associated with appendiceal perforation. aim of this retrospective study is therefore to investigate if hyperbilirubinaemia has a diagnostic value for the pre-operative diagnosis of appendiceal perforation in patients with appendicitis.

we identified 538 patients with histologically proved acute appendicitis who underwent laparoscopic or conventional appendicectomy between january, 2004 and december, 2007 in a surgical department of an academic teaching hospital. a retrospective multiple chart review of the medical records including laboratory values (bilirubin, crp, white blood count) and histological results was conducted.

Eligibility criteria:
inclusion criteria: * appendicitis and a preoperative laboratory workup with leukocytes, c-reactive protein, bilirubin and liver transaminases got and gpt exclusion criteria: * alcoholism * a history of viral hepatitis * gilbert's disease * dubin johnson syndrome * bric (benign recurrent intra-hepatic cholestasis) and other documented biliary * hemolytic or liver diseases associated with hyperbilirubinaemia.
a randomized controlled trail comparing subthalamic and pallidal deep brain stimulation for dystonia

Conditions: Dystonia

Summary: the purpose of this study was to compare the subthalamic nucleus(stn) with the globus pallidus internus(gpi) as a stimulation target for deep brian stimulation(dbs) for medically refractory dystonia.

in this prospective randomized controlled study,elecrodes were bilaterally implanted in stn and gpi of 40 patients with dystonia.

Eligibility criteria:
inclusion criteria: 1. subject is aged 18 to 75 years old, male or female. 2. diagnosed with cervical dystonia by a movement disorders neurologist. 3. has cervical dystonia alone, not generalized or multifocal. 4. has had adequate trials of medical therapy. exclusion criteria: 1. cognitive impairment. 2. abnormalities on pre-operative magnetic resonance imaging (mri). 3. medical conditions precluding general anaesthetic or surgery. 4. unstable psychiatric disease. 5. previous brain lesions to treat cervical dystonia. 6. attended some other trials within three month.
contribution of lower limb venous colour doppler ultrasound in the diagnosis of pulmonary embolism recurrence

Conditions: Pulmonary Embolism

Summary: venous thromboembolic disease is a clinical entity including pulmonary embolism (pe) and deep vein thrombosis (dvt). it is a chronic disease with 30% recurrence rate at 10 years. in patients with recurrent pe clinical suspicion, an objective and accurate diagnostic method/strategy is warranted to exclude or confirm a pe new episode diagnosis and to decide on treatment initiation. recurrent pe diagnosis raises several issues related to the limitations of clinical scores, d-dimer testing, and diagnostic imaging used for a first episode diagnosis. most importantly, residual obstruction on chest imaging reported in more than 50% of cases at 6 months can make it difficult to distinguish between an old and a new thrombosis in the absence of possible comparison with a previous imaging carried out under the same modalities. there are currently few recommendations about the diagnostic strategy for patients with a recurrent pe clinical suspicion and these recommendations are not very consistent due to the lack of a validated strategy. none of current guidelines have included imaging-detectable lower-limb dvt within the strategies despite a reported high prevalence of pe-associated dvt. in one study using venography, 82% (95% ci 76.5 - 86.9) of angiographically-proven pe patients had an associated proximal or distal deep vein thrombosis, of which 42% were asymptomatic. in another study using lower-limb venous ultrasound, a proximal or distal dvt was detected in 93% (95% ci 85-97) of patients with pe.

in this study, patients with pe clinical suspicion and a previous pe episode have a standard diagnostic work-up based on clinical probability assessment, d-dimer testing and diagnostic imaging (pulmonary ct angiography, ventilation perfusion scan). a bilateral lower-limb venous colour doppler ultrasound (cdus) is performed in parallel in these patients as usually carried out in our hospital for the diagnosis management of patients with clinically suspected pe. this test is performed and interpreted by an independent sonographer unaware of the results of the standard diagnostic work-up. lower-limb venous cdus is then compared to the results of the standard work-up as interpreted during expert panel meetings by members involved in the diagnosis and management of patients with pe and dvt. data will be collected both retrospectively and prospectively.

Eligibility criteria:
inclusion criteria: * adult consecutive patients (\>= 18 years old) * hospitalized for clinical suspicion of pulmonary embolism recurrence with at least one of the following symptoms: acute dyspnea or worsening of chronic dyspnea, chest pain, hemoptysis or syncope exclusion criteria: * time between onset of symptoms and diagnosis \> 15 days * pregnant women * contra-indication to ct pulmonary angiography * lower-limb cdus not possible to perform for technical reasons * lung scans not possible to perform for technical reasons

Keywords: pulmonary embolism deep vein thrombosis recurrence diagnosis strategy colour doppler ultrasound
a clinical study to observe how well that bat8006 works on patients with platinum resistance ovarian cancer

Conditions: Platinum-resistant Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer

Summary: this is a phase 1b/2, open-label, 2-part, global study designed to investigate the anti-tumor activity as well as the safety and efficacy of bat8006 in subjects with platinum resistance ovarian cancer

part 1 is a dose finding study. the rp2d will be confirmed in part 1, and this rp2d will be further evaluated in part 2. in part 1, pk samples will be collected and analyzed to support the determination of rp2d. three dose cohorts are planned. subjects will be assigned to these three dosages in parallel. part 2 will expose subjects at the rp2d confirmed in part 1.

Eligibility criteria:
inclusion criteria: 1. able to give voluntary informed consent and understand the study and are willing to follow and complete all the study required procedures. 2. women ≥ 18 years old. 3. subjects with histologically or cytologically confirmed platinum-resistant, advanced or metastatic epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. 4. presence of at least one measurable lesion per recist v1.1. that was not in a prior radiation or other locally treated area. 5. life expectancy ≥ 3 months. 6. adequate hematological, liver, kidney and coagulation function. exclusion criteria 1. females who are pregnant or nursing. 2. had major surgery within 28 days of the screening visit. 3. history of autologous transplantation ≤ 3 months 4. history of severe infection deemed clinically significant by the pi or designee within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose of study drug. 5. history of human immunodeficiency virus (hiv) infection. 6. active hepatitis b or c. 7. any other serious underlying medical. 8. received cancer-directed therapy within the timeframes. 9. subjects have other active malignancies within 5 years prior to the first dose. 10. known allergies, hypersensitivity, or intolerance to the study drug or its excipients. 11. vaccinated with any live-attenuated vaccine within 4 weeks. 12. subjects with known history of psychiatric disorders, drug abuse, alcoholism or drug addiction. 13. subjects who are estimated by the investigator to have poor compliance with the clinical study or who have other factors that are not appropriate to participate in the study in the opinion of the investigator.
seladelpar in subjects with primary biliary cholangitis (pbc) and compensated cirrhosis

Conditions: Primary Biliary Cholangitis

Summary: to evaluate the effect of seladelpar on clinical outcomes in patients with primary biliary cholangitis (pbc) and compensated cirrhosis.

to evaluate the effect of seladelpar on clinical outcomes in patients with primary biliary cholangitis (pbc) and compensated cirrhosis.

Eligibility criteria:
inclusion criteria: individuals must meet the following criteria to be eligible for study participation: 1. must be at least 18 years old. 2. must have a confirmed prior diagnosis of pbc 3. evidence of cirrhosis 4. cp score a or b 5. females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. male individuals who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose 6. individuals must be able to comply with the instructions for study drug administration and be able to complete the study schedule of assessments (soa) exclusion criteria: individuals must not meet any of the following criteria to be eligible for study participation: 1. prior exposure to seladelpar 2. a medical condition other than pbc that, in the investigator's opinion, would preclude full participation in the study 3. history of liver transplantation or actively listed for cadaveric or planned living donor transplant. 4. decompensated cirrhosis 5. evidence of portal vein thrombosis based on imaging at time of screening by doppler ultrasound or prior evidence by ct or mri 6. hospitalization for liver-related complication within 12 weeks of screening 7. laboratory parameters at screening: 1. alkaline phosphatase (alp) \< 1.5× upper limit of normal (uln) or ≥ 10×uln 2. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≥5×uln 3. total bilirubin (tb) ≥5×uln 4. platelet count ≤50×10\^3/µl 5. albumin ≤2.8 g/dl 6. estimated glomerular filtration rate (egfr) \<45 ml/min/1.73 m\^2 7. meld score \>12. for individuals on anticoagulation medication, baseline international normalized ratio (inr) determination for meld score calculation should take anticoagulant use into account, in consultation with the medical monitor. 8. serum alpha-fetoprotein (afp) \>20 ng/ml 9. inr \>1.7 8. cp-c cirrhosis 9. history or presence of other concomitant liver diseases

Keywords: primary biliary cholangitis (pbc) pbc
validity and reliability of the two-minute step test in traumatic meniscal tear

Conditions: Meniscus Tear

Summary: this study is designed to explore the validity and reliability of the two-minute step test as an assessment method for functional capacity in patients diagnosed with traumatic meniscal tear. the objective is to determine the effectiveness of this test in accurately measuring the functional abilities of individuals with traumatic meniscus tears. by focusing on patients who have been diagnosed with such injuries and employing the two-minute step test, the study aims to provide valuable insights into the suitability of this evaluation tool for assessing functional capacity in this specific patient population. the findings of this research have the potential to contribute significantly to the clinical understanding and management of traumatic meniscal tears, offering clinicians a reliable and valid method for evaluating the functional capabilities of affected individuals.

the study is planned as a cross-sectional clinical study. fifty-five patients diagnosed with traumatic meniscal tear who apply to the istanbul physical medicine and rehabilitation training and research hospital clinics will be included in the study. patients must have a previous diagnosis of traumatic meniscal tear based on magnetic resonance imaging. sociodemographic data such as age, height, weight, body mass index, marital status, education level, and occupation will be recorded. the level of impairment in daily activities of patients with meniscal tear will be assessed using the western ontario meniscus evaluation questionnaire. pain intensity will be evaluated using the visual analog scale, a linear scale of 10 cm. the pain catastrophizing scale will be used to assess the patient's level of distress due to pain. the patient's confidence level in performing different activities due to pain will be evaluated using the pain self-efficacy questionnaire. the patient's physical function will be assessed using the 2-minute steptest. this test, to be administered by the same evaluator, requires the patient to have rested for at least 30 minutes before starting, and there will be a minimum of 1 hour of rest between the tests conducted. before starting the tests, the patient's blood pressure, oxygen saturation, and heart rate will be measured, and if results are outside the normal range, the test will not proceed.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 50 who have previously been diagnosed with traumatic meniscal tear through magnetic resonance imaging will be included in the study exclusion criteria: * patients under the age of 18 and over the age of 50 * patients with accompanying knee osteoarthritis * degenerative meniscal tears * uncontrolled hypertension * decompensated cardiac failure * presence of systemic diseases affecting lower limb functions * presence of degenerative diseases affecting lower limb functions * peripheral artery disease causing vascular claudication * psychiatric illness * neuromuscular disease

Keywords: exercise test meniscus physical fitness
vaginal clindamycin cream plus vaginal probiotic for bacterial vaginosis

Conditions: Bacterial Vaginosis Treatment

Summary: vaginal clindamycin cream plus vaginal probiotic for treatment of bacterial vaginosis

vaginal clindamycin cream was used initially for treatment of bacterial vaginosis followed by vaginal probiotic either in cnotinous or interrupted manner, then assessment of the results of treatment at different time intervals was done.

Eligibility criteria:
inclusion criteria: * more than 18 years * has recurrent bacterial vaginosis exclusion criteria: * pregnancy * use of other antmicrobial * not provide informed consent
frailty assessment among kidney transplant candidates

Conditions: Frailty; Kidney Transplant; Complications

Summary: frailty is common among chronic kidney disease patients who are on the kidney transplant (kt) waiting list. the aim of this study is to assess frailty according to different frailty tools among kt candidates and to establish potential biomarkers of frailty.

this is an observational study where kt candidates will be assessed for frailty according to: * frailty fried phenotype and * frail scale sociodemographics and clinical variables will be collected and serum samples will be obtained in order to implement further studies regarding biomarkers of frailty..

Eligibility criteria:
inclusion criteria: * kt candidates accepted for the kt waiting list exclusion criteria: * no willing for participating * difficulty in understanding spanish or english
observational study of incidence rates of esophageal cancer in women taking medications for the prevention or treatment of osteoporosis (mk-0217a-352)

Conditions: Esophageal Cancer; Squamous Cell Carcinoma; Adenocarcinoma

Summary: this is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.


Eligibility criteria:
inclusion criteria: * cases: * women in the database aged 55 or older between 1996 and 2008 with diagnosis of esophageal cancer * comparator controls: * each case was matched to all women in the random subcohort of 25,000 who had the same year of birth as the case and were in the database at the time of diagnosis. exclusion criteria: * women with diagnosis of any other cancer or paget's disease or who have received oral or intravenous steroids before the index date